CorMedix Inc.
CorMedix Inc. (Nasdaq: CRMD) is a biopharmaceutical company that develops and commercializes therapies for serious diseases and conditions. Its primary product, DefenCath, is an antimicrobial and anticoagulant catheter-lock solution approved to reduce catheter-related bloodstream infections in adults with kidney… From the company’s description.
Over the twelve months to Jun 30, 2026, CorMedix Inc. reported revenue of $462.25M, up 280.5% from a year earlier, and net income of $187.17M. Its operating margin was 47.0%, and operations generated $253.94M in cash. In fiscal 2025, it reported revenue of $311.71M, up 617.0% from fiscal 2024, and net income of $163.06M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What CorMedix Inc. does
In the company’s own words
CorMedix Inc. (Nasdaq: CRMD) is a biopharmaceutical company that develops and commercializes therapies for serious diseases and conditions. Its primary product, DefenCath, is an antimicrobial and anticoagulant catheter-lock solution approved to reduce catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter; the company launched it in the United States in 2024 and sells it to dialysis clinics and hospitals. In August 2025, CorMedix acquired Melinta Therapeutics, adding six marketed anti-infective products and a cardiovascular medicine. The portfolio includes REZZAYO, an intravenous antifungal; MINOCIN IV and VABOMERE, intravenous antibiotics; the single-dose antibiotics ORBACTIV and KIMYRSA; BAXDELA, available in intravenous and oral forms; and TOPROL-XL, a cardiovascular product. CorMedix promotes DefenCath, REZZAYO, MINOCIN IV and VABOMERE, while providing more limited promotional support for other acquired products. It also pursues additional indications for DefenCath and REZZAYO.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PARSIPPANY, NJ
- Fiscal year end
- December
- CIK
- 1410098
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns CorMedix Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · CorMedix Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
CorMedix Inc.’s bonds, as funds hold them
Funds report holding 1 issues of CorMedix Inc.’s debt, $3.19M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.00%, maturing 2030 to 2030.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do CorMedix Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of CorMedix Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in CorMedix Inc.'s last four quarterly filings that the numbers alone won't show?”